HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Nanotech safety

This article was originally published in The Rose Sheet

Executive Summary

"Many nanotech companies and laboratories believe nanoparticles - specks of matter that are smaller than living cells - may pose specific environmental and health risks to workers," according to a Nov. 13 release from the International Council on Nanotechnology (ICON). The multi-stakeholder group acknowledges that risks to workers - who represent the front lines of the nanotech revolution and interact with the materials in their raw form - are likely greater than those to consumers. However, the research at issue - commissioned by ICON from the University of California, Santa Barbara, which surveyed 64 organizations across the globe - could be employed by activists as evidence that sunscreens and cosmetics containing engineered nanoparticles demand more intensive study and stricter FDA regulation (1"The Rose Sheet" May 22, 2006, p. 3). The report is available at 2http://icon.rice.edu...

Latest Headlines
See All
UsernamePublicRestriction

Register

RS014358

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel